Core Viewpoint - The resumption of the fifth set of standards for the Sci-Tech Innovation Board (STAR Market) is expected to revitalize the biopharmaceutical industry, which has faced a capital winter over the past two years, providing new investment opportunities and hope for long-term, capital-intensive projects [3][4][5]. Group 1: Industry Overview - The approval of Wuhan Heyuan Biotechnology Co., Ltd. (Heyuan Bio) marks the first company to pass under the restarted fifth set of standards, indicating significant market expectations and a renewed focus on the biopharmaceutical sector [3][5]. - The biopharmaceutical industry is characterized by long cycles and substantial capital requirements, making stable policy support crucial for its growth [7][8]. Group 2: Investment Insights - Investors are concerned about whether the approval standards have been raised, with expectations that companies may need to provide more robust clinical data, potentially requiring phase III clinical trials for approval [8][9]. - The commercial viability and profitability of biopharmaceutical companies will be critical under the new standards, with a focus on meeting unmet clinical needs and maintaining competitive positioning in the market [10][9]. Group 3: Company Case Study - Heyuan Bio's core product, HY1001, has completed phase III clinical trials and is projected to launch in 2025, with expectations of significant sales starting in 2026 and profitability by 2027 [9][10]. - The company has established a sales network across over 30 provinces in China through agreements with major distributors, enhancing its market presence [9]. Group 4: Market Trends - The successful listing of Heyuan Bio may lead to a resurgence of interest in Pre-IPO and mid-stage biopharmaceutical investments, which had previously stagnated due to market conditions [15][16]. - The current market environment is seeing a shift towards more rational investment behavior, with investors becoming more cautious after previous market downturns, yet maintaining a long-term optimistic outlook for the industry [17][18].